PRAX, US74006W2070

Praxis Precision Medicines stock fell 1.21 percent as Q2 costs rose

Published on 10/07/2026 at 05:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Praxis Precision Medicines stock reported diluted EPS of USD -2.87 for Q2 2026, beating consensus by USD 0.80. Operating expenses reached USD 96.9 million.

PRAX, US74006W2070, Illustration mit AI erstellt.

Praxis Precision Medicines stock (ISIN US74006W2070) was last at USD 280.14 on Nasdaq on October 6, 2026, down 1.21 percent from USD 283.56. The latest Q2 2026 update showed a USD 0.80 diluted EPS beat against consensus, while the company continued building for two potential product launches.

Q2 costs rise before launches

According to Benzinga on October 6, 2026, Praxis reported Q2 2026 operating expenses of USD 96.9 million, up from USD 76.0 million in Q2 2025. Research and development accounted for USD 69.4 million, while general and administrative expenses were USD 27.5 million.

The expense increase reflects a company moving toward commercialization rather than a revenue-driven expansion. According to Benzinga, operating cash use reached USD 78 million in Q2 2026, compared with USD 55 million in Q2 2025.

Cash supports regulatory timetable

Praxis ended Q2 2026 with USD 1.4 billion in cash, cash equivalents and marketable securities, compared with USD 926 million on December 31, 2025, according to Benzinga. Management said the balance supports a runway into 2028, giving the company room to fund launch preparations while the FDA reviews its lead programs.

The regulatory calendar remains the central valuation driver. The Q2 update said the FDA found no efficacy-related significant issues in its mid-cycle review of ulixacaltamide and did not plan an advisory committee meeting. For relutrigine, the PDUFA target moved to December 27, 2026 after additional sensitivity analysis was classified as a major amendment.

Analyst targets remain elevated

According to MarketBeat on October 6, 2026, BTIG Research raised its price target from USD 810.00 to USD 826.00 and retained a Buy rating. MarketBeat listed a Moderate Buy consensus, 20 analyst ratings and an average target of USD 613.26. The target lies 118.9 percent above the October 6 price.

The contrast is clear: quarterly EPS beat expectations, but operating expenses and cash use are rising as approval and launch milestones approach. For investors, the next test is whether the regulatory timeline converts the cash-funded commercial build into approved products.

PRAX stays below yearly high

PRAX was last at USD 280.14 on Nasdaq on October 6, 2026, with a session range of USD 272.17 to USD 289.47. Its 52-week range was USD 50.31 to USD 392.70, placing the stock 28.7 percent below the high, while market capitalization stood at USD 7.8 billion.